{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:46:41Z","timestamp":1774122401395,"version":"3.50.1"},"reference-count":42,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A hemolysis-linked subphenotype of sickle cell disease (SCD), characterized by pulmonary hypertension, stroke, priapism and leg ulcers, is associated with decreased nitric oxide bioavailability and vasculopathy. Vasculopathy appears to have a multifactorial etiology, including mechanisms primarily that involve deficient nitric oxide (NO) signaling, but also involving altered function of NO synthase related to substrate availability and cooperating factors such as apolipoproteins. Improved understanding of the vascular pathophysiology of SCD has led to new vascular targets for translational research in SCD. This growing vascular therapeutics field in SCD is complementary to the ongoing efforts to reduce the morbidity of vaso-occlusive pain crisis. This presentation will review the current biology and translational clinical development of novel small molecules targeting sickle cell vasculopathy. Strategies targeting the hemeoxygenase-carbon monoxide pathway, the arginine-NO synthase-cGMP-phosphodiesterase 5 pathway, the nitrate-nitrite-NO pathway, and the apolipoprotein A-I pathways will be reviewed. In this context, current clinical trials of inhaled NO, CO, nitrite, sildenafil and apoA-I mimetics will be discussed.<\/jats:p>","DOI":"10.1182\/asheducation-2008.1.186","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T10:12:58Z","timestamp":1228990378000},"page":"186-192","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I"],"prefix":"10.1182","volume":"2008","author":[{"given":"Gregory J.","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111708332379500_R1","doi-asserted-by":"crossref","unstructured":"Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004;11:129\u2013151.","DOI":"10.1080\/mic.11.2.129.151"},{"key":"2019111708332379500_R2","doi-asserted-by":"crossref","unstructured":"Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21:37\u201347.","DOI":"10.1016\/j.blre.2006.07.001"},{"key":"2019111708332379500_R3","doi-asserted-by":"crossref","unstructured":"Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383\u20131389.","DOI":"10.1038\/nm1202-799"},{"key":"2019111708332379500_R4","doi-asserted-by":"crossref","unstructured":"Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension and mortality in sickle cell disease. JAMA. 2005;294:81\u201390.","DOI":"10.1001\/jama.294.1.81"},{"key":"2019111708332379500_R5","doi-asserted-by":"crossref","unstructured":"Kato GJ, McGowan VR, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension and death in patients with sickle cell disease. Blood. 2006;107:2279\u20132285.","DOI":"10.1182\/blood-2005-06-2373"},{"key":"2019111708332379500_R6","doi-asserted-by":"crossref","unstructured":"Pawloski JR, Hess DT, Stamler JS. Impaired vasodilation by red blood cells in sickle cell disease. Proc Natl Acad Sci U S A. 2005;102:2531\u20132536.","DOI":"10.1073\/pnas.0409876102"},{"key":"2019111708332379500_R7","doi-asserted-by":"crossref","unstructured":"Isbell TS, Sun CW, Wu LC, et al. SNO-hemoglobin is not essential for red blood cell-dependent hypoxic vasodilation. Nat Med. 2008;14:773\u2013777.","DOI":"10.1038\/nm1771"},{"key":"2019111708332379500_R8","unstructured":"Morris CR, Morris SM, Jr., Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003;168:63\u201369."},{"key":"2019111708332379500_R9","doi-asserted-by":"crossref","unstructured":"Kaul DK, Zhang X, Dasgupta T, Fabry ME. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis and oxidative stress. Am J Physiol Heart Circ Physiol. 2008;295:H39\u201347.","DOI":"10.1152\/ajpheart.00162.2008"},{"key":"2019111708332379500_R10","doi-asserted-by":"crossref","unstructured":"Romero JR, Suzuka SM, Nagel RL, Fabry ME. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood. 2002;99:1103\u20131108.","DOI":"10.1182\/blood.V99.4.1103"},{"key":"2019111708332379500_R11","doi-asserted-by":"crossref","unstructured":"Dasgupta T, Hebbel RP, Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med. 2006;41:1771\u20131780.","DOI":"10.1016\/j.freeradbiomed.2006.08.025"},{"key":"2019111708332379500_R12","unstructured":"Waugh WH, Daeschner CW, III, Files BA, McConnell ME, Strandjord SE. Oral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase two results. J Natl Med Assoc. 2001;93:363\u2013371."},{"key":"2019111708332379500_R13","doi-asserted-by":"crossref","unstructured":"Waugh WH. Simplified method to assay total plasma peroxidase activity and ferriheme products in sickle cell anemia, with initial results in assessing clinical severity in a trial with citrulline therapy. J Pediatr Hematol Oncol. 2003;25:831\u2013834.","DOI":"10.1097\/00043426-200310000-00021"},{"key":"2019111708332379500_R14","doi-asserted-by":"crossref","unstructured":"Niihara Y, Matsui NM, Shen YM, et al. L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Blood Disord. 2005;5:4.","DOI":"10.1186\/1471-2326-5-4"},{"key":"2019111708332379500_R15","doi-asserted-by":"crossref","unstructured":"Williams R, Olivi S, Li CS, et al. Oral glutamine supplementation decreases resting energy expenditure in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 2004;26:619\u2013625.","DOI":"10.1097\/01.mph.0000140651.65591.b8"},{"key":"2019111708332379500_R16","doi-asserted-by":"crossref","unstructured":"Morris CR, Suh JH, Hagar W, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood. 2008;111:402\u2013410.","DOI":"10.1182\/blood-2007-04-081703"},{"key":"2019111708332379500_R17","doi-asserted-by":"crossref","unstructured":"Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA. 2003;289:1136\u20131142.","DOI":"10.1001\/jama.289.9.1136"},{"key":"2019111708332379500_R18","doi-asserted-by":"crossref","unstructured":"Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol. 2005;130:445\u2013453.","DOI":"10.1111\/j.1365-2141.2005.05625.x"},{"key":"2019111708332379500_R19","unstructured":"Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica. 2005;90:452\u2013458."},{"key":"2019111708332379500_R20","doi-asserted-by":"crossref","unstructured":"Bialecki ES, Bridges KR. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med. 2002;113:252.","DOI":"10.1016\/S0002-9343(02)01165-8"},{"key":"2019111708332379500_R21","doi-asserted-by":"crossref","unstructured":"Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3:1077\u20131084.","DOI":"10.1111\/j.1743-6109.2006.00333.x"},{"key":"2019111708332379500_R22","doi-asserted-by":"crossref","unstructured":"Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A. 2005;102:1661\u20131666.","DOI":"10.1073\/pnas.0407183102"},{"key":"2019111708332379500_R23","doi-asserted-by":"crossref","unstructured":"Dezfulian C, Raat N, Shiva S, Gladwin MT. Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc Res. 2007;75:327\u2013338.","DOI":"10.1016\/j.cardiores.2007.05.001"},{"key":"2019111708332379500_R24","unstructured":"Mack AK, McGowan VR, Tremonti CK, et al. Sodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I\/II study. Br J Haematol. In press."},{"key":"2019111708332379500_R25","doi-asserted-by":"crossref","unstructured":"Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. 2008;7:156\u2013167.","DOI":"10.1038\/nrd2466"},{"key":"2019111708332379500_R26","doi-asserted-by":"crossref","unstructured":"Webb AJ, Patel N, Loukogeorgakis S, et al. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension. 2008;51:784\u2013790.","DOI":"10.1161\/HYPERTENSIONAHA.107.103523"},{"key":"2019111708332379500_R27","doi-asserted-by":"crossref","unstructured":"Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J. 2002;144:165\u2013172.","DOI":"10.1067\/mhj.2002.123145"},{"key":"2019111708332379500_R28","doi-asserted-by":"crossref","unstructured":"Ou J, Ou Z, Jones DW, et al. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation. 2003;107:2337\u20132341.","DOI":"10.1161\/01.CIR.0000070589.61860.A9"},{"key":"2019111708332379500_R29","doi-asserted-by":"crossref","unstructured":"Ergul S, Brunson CY, Hutchinson J, et al. Vasoactive factors in sickle cell disease: in vitro evidence for endothelin-1-mediated vasoconstriction. Am J Hematol. 2004;76:245\u2013251.","DOI":"10.1002\/ajh.20107"},{"key":"2019111708332379500_R30","doi-asserted-by":"crossref","unstructured":"Graido-Gonzalez E, Doherty JC, Bergreen EW, Organ G, Telfer M, McMillen MA. Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis. Blood. 1998;92:2551\u20132555.","DOI":"10.1182\/blood.V92.7.2551"},{"key":"2019111708332379500_R31","doi-asserted-by":"crossref","unstructured":"Rivera A. Reduced sickle erythrocyte dehydration in vivo by endothelin-1 receptor antagonists. Am J Physiol Cell Physiol. 2007;293:C960\u2013C966.","DOI":"10.1152\/ajpcell.00530.2006"},{"key":"2019111708332379500_R32","doi-asserted-by":"crossref","unstructured":"Sabaa N, de Franceschi L, Bonnin P, et al. Endothelin receptor antagonism prevents hypoxia-induced mortality and morbidity in a mouse model of sickle-cell disease. J Clin Invest. 2008;118:1924\u20131933.","DOI":"10.1172\/JCI33308"},{"key":"2019111708332379500_R33","doi-asserted-by":"crossref","unstructured":"Ryter SW, Kim HP, Nakahira K, Zuckerbraun BS, Morse D, Choi AM. Protective functions of heme oxygenase-1 and carbon monoxide in the respiratory system. Antioxid Redox Signal. 2007;9:2157\u20132173.","DOI":"10.1089\/ars.2007.1811"},{"key":"2019111708332379500_R34","doi-asserted-by":"crossref","unstructured":"Nath KA, Grande JP, Haggard JJ, et al. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol. 2001;158:893\u2013903.","DOI":"10.1016\/S0002-9440(10)64037-0"},{"key":"2019111708332379500_R35","doi-asserted-by":"crossref","unstructured":"Jison ML, Munson PJ, Barb JJ, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004;104:270\u2013280.","DOI":"10.1182\/blood-2003-08-2760"},{"key":"2019111708332379500_R36","doi-asserted-by":"crossref","unstructured":"Belcher JD, Mahaseth H, Welch TE, Otterbein LE, Hebbel RP, Vercellotti GM. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest. 2006;116:808\u2013816.","DOI":"10.1172\/JCI26857"},{"key":"2019111708332379500_R37","doi-asserted-by":"crossref","unstructured":"Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350:886\u2013895.","DOI":"10.1056\/NEJMoa035477"},{"key":"2019111708332379500_R38","doi-asserted-by":"crossref","unstructured":"Ataga KI, Sood N, De GG, et al. Pulmonary hypertension in sickle cell disease. Am J Med. 2004;117:665\u2013669.","DOI":"10.1016\/j.amjmed.2004.03.034"},{"key":"2019111708332379500_R39","doi-asserted-by":"crossref","unstructured":"Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood. 2008;111:3991\u20133997.","DOI":"10.1182\/blood-2007-08-110098"},{"key":"2019111708332379500_R40","doi-asserted-by":"crossref","unstructured":"Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995;86:776\u2013783.","DOI":"10.1182\/blood.V86.2.776.bloodjournal862776"},{"key":"2019111708332379500_R41","doi-asserted-by":"crossref","unstructured":"Billett HH, Nagel RL, Fabry ME. Paradoxical increase of painful crises in sickle cell patients with alpha-thalassemia. Blood. 1995;86:4382.","DOI":"10.1182\/blood.V86.11.4382a.bloodjournal86114382a"},{"key":"2019111708332379500_R42","doi-asserted-by":"crossref","unstructured":"Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317\u20131322.","DOI":"10.1056\/NEJM199505183322001"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/186\/786478\/186_192ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/186\/786478\/186_192ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T08:33:38Z","timestamp":1573979618000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2008\/1\/186\/95819\/Novel-Small-Molecule-Therapeutics-for-Sickle-Cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2008.1.186","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}